NEW YORK - Establishment Labs Holdings Inc . (NASDAQ: NASDAQ:ESTA), a medical technology company focused on women's health, particularly in breast aesthetics and reconstruction, has announced the appointment of Jeff Ehrhardt as General Manager of North America. Ehrhardt, with over 25 years of experience at Allergan (NYSE:AGN) Aesthetics, is set to oversee the anticipated U.S. launch of Motiva implants later this year.
Ehrhardt's career includes a recent stint as General Manager for Plastic Surgery & Regenerative Medicine at Allergan Aesthetics, where he managed the company's breast implants portfolio and led sales and marketing strategies in the U.S. His extensive background in the industry also includes various leadership roles and an educational foundation with a bachelor's degree in business and an MBA.
Juan José Chacón-Quirós, CEO and Founder of Establishment Labs, expressed confidence in Ehrhardt's ability to introduce Motiva to the U.S. market, aiming to set a new standard in breast augmentation and reconstruction. Ehrhardt shared his enthusiasm for joining Establishment Labs, emphasizing the company's commitment to science and innovation, and its potential to enhance surgical outcomes and expand market share.
While Establishment Labs' Motiva silicone gel-filled implants are not yet approved for commercial distribution in the United States, they are currently undergoing clinical investigation as per FDA regulations for investigational devices.
The company's global presence includes over three million devices delivered to surgeons in over 85 countries, supported by extensive patent applications and scientific research.
This news is based on a press release statement.
InvestingPro Insights
As Establishment Labs Holdings Inc. (NASDAQ: ESTA) gears up for the potential U.S. launch of Motiva implants, key financial metrics from InvestingPro provide a snapshot of the company's current market position. With a market capitalization of approximately $1.37 billion, the company's valuation reflects significant investor interest. However, the Price to Earnings (P/E) ratio stands at a negative -17.49 based on the last twelve months as of Q4 2023, indicating that the company is not currently profitable. Additionally, the Price to Book (P/B) ratio is notably high at 74.65, which could suggest that the stock is priced at a premium relative to the company's net asset value.
Despite these valuation concerns, ESTA has displayed a strong performance in the short term, with a three-month price total return of 31.54% and a significant six-month return of 58.51%. These figures may reflect market optimism about the company's growth prospects and the upcoming product launches.
For investors looking for a deeper dive into Establishment Labs' financial health and future prospects, InvestingPro offers additional insights. Notably, the company's liquid assets exceed short-term obligations, providing some financial stability. However, analysts are cautious, as they do not anticipate the company will be profitable this year, and the valuation implies a poor free cash flow yield. For those considering an investment, there are further InvestingPro Tips available, detailing aspects such as the company's lack of dividend payments and its performance over various time frames. In total, there are 9 InvestingPro Tips for ESTA, which can be found at https://www.investing.com/pro/ESTA.
Interested readers can explore these insights and more, and take advantage of a special offer using coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.